Convalescent plasma: New evidence for an old therapeutic tool?

Blood Transfusion

Volumn 14, Issue 2, 2016, Pages 152-157

  Marano, Giuseppe ^a   Vaglio, Stefania ^a,b   Pupella, Simonetta ^a   Facco, Giuseppina ^a,c   Catalano, Liviana ^a   Liumbruno, Giancarlo M ^a   Grazzini, Giuliano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Azienda Ospedaliera Città della Salute e della Scienza   (Italy)

Author keywords

Convalescent plasma; Ebola virus; Emergent pathogens; Passive immunisation; Transfusion safety

Indexed keywords

ANTIVIRUS AGENT; EBOLA VACCINE;

ANTIBODY TITER; ANTIVIRAL THERAPY; BLOOD; BLOOD DONOR; BLOOD SAFETY; CONVALESCENCE; CONVALESCENT BLOOD PRODUCT; CONVALESCENT PLASMA; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; HUMAN; INFECTION; INFECTION PREVENTION; NONHUMAN; PASSIVE IMMUNIZATION; PLASMA; PLASMA TRANSFUSION; REVIEW; UNCERTAINTY; AFRICA; BLOOD COMPONENT THERAPY; EPIDEMIC; HEMORRHAGIC FEVER, EBOLA;

AFRICA, WESTERN; BLOOD COMPONENT TRANSFUSION; CONVALESCENCE; DISEASE OUTBREAKS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; PLASMA;

EID: 84961626292     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2015.0131-15     Document Type: Review

References (81)

1. Rajam G, Sampson J, Carlone GM, Ades EW. An augmented passive immune therapy to treat fulminant bacterial infections. Recent Pat Antiinfect Drug Discov 2010; 5: 157-67.
2. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000; 13: 602-14.
3. Virdi V, Depicker A. Role of plant expression systems in antibody production for passive immunization. Int J Dev Biol 2013; 57: 587-93.
4. Burnouf T, Seghatchian J. Ebola virus convalescent blood products: where we are now and where we may need to go. Transfus Apher Sci 2014; 51: 120-5.
5. World Health Organization. Position Paper on collection and use of convalescent plasma or serum as an element in filovirus outbreak response. WHO Blood Regulators Network (BRN). 14 August 2014. Geneva: World Health Organization; 2014.
6. Dodd RY Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Br J Haematol 2012; 159: 135-42.
7. Lai KY, Ng WY, Cheng FF. Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect Dis Pov 2014; 3: 43.
8. World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Interim guidance for national health authorities and blood transfusion services. Geneva: World Health Organization; September 2014. Available at: http://apps.who.int/iris/bitstream/10665/135591/1/WHO-HIS-SDS-2014.8-eng.pdf?ua=1. Accessed on 21/05/2015.
9. Simon J. Emil Behring's medical culture: from disinfection to serotherapy. Med Hist 2007; 51: 201-18.
10. Behring E, Kitasato S. Ueber das Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitat bei thieren. Deutsche medizinsche Wochenschrift 1890; 16: 1113-4.
11. In: Milestones in Microbiology: 1556 to 1940. Brock TD, editor. Washington: ASM Press; 1998. p. 138.
12. Luke TC, Casadevall A, Watowich SJ, et al. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 2010; 38: e66-73.
13. Francis FD, Hall MW, Gaines AR. Early use of convalescent serum in influenza. Mil Surg 1920; 47: 177-9.
14. Redden WR Treatment of influenza-pneumonia by use of convalescent human serum. Boston Med Surg J 1919; 161: 688-91.
15. Jacobaeus. Treatment of influenza pneumonia with serum from convalescents. Svenska Lakartidnin 1920; 18: 385-99.
16. Bogardus FB Influenza pneumonia treated by blood transfusions. NY Med J 1919; 109: 765.
17. Miller OO, McConnell WT. Report of influenza treated with serum from recovered cases. Ky Med J 1919; 17: 218-9.
18. Carlyle PM Injection of whole blood in influenza. Br Med J 1919; 1: 698.
19. Lesne E, Brodin P, Saint-Girons F. Plasma therapy in influenza. Presse Med 1919; 27: 181-2.
20. Hemming VG Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol 2001; 8: 859-63.
21. Nour B, Green M, Michaels M, et al. Parvovirus B19 infection in pediatric transplant patients. Transplantation 1993; 56: 835-8.
22. World Health Organization Mers-Cov Research Group. State of knowledge and data gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in humans. PLoS Curr 2013; 12: 5.
23. Zingher A, Mortimer P. Convalescent whole blood, plasma and serum in the prophylaxis of measles: JAMA 12 April, 1926; 1180-1187. Rev Med Virol 2005; 15: 407-21.
24. Young MK, Nimmo GR, Cripps AW, Jones MA. Post-exposure passive immunisation for preventing measles. Cochrane Database Syst Rev 2014; 4: CD010056.
25. Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003; 9: 199-201.
26. Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J 2006; 12: 489.
27. Beigel JH, Luke TC. A study in scarlet - convalescent plasma for severe influenza. Crit Care Med 2012; 40: 1027-28.
28. Leider JP, Brunker PA, Ness PM. Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? Transfusion 2010; 50: 1384-98.
29. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357: 1450-1.
30. Hui DS, Lee N. Adjunctive therapies and immunomodulating agents for severe influenza. Influenza Other Resp Viruses 2013; 7 (Suppl. 3): 52-9.
31. Prince GA, Hemming VG, Horswood RL, et al. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol 1987; 61: 1851-4.
32. Mozdzanowska K, Furchner M, Washko G, et al. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 1997; 71: 4347-55.
33. Simmons CP, Bernasconi NL, Suguitan AL, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4: e178.
34. Jahrling PB, Frame JD, Rhoderick JB, Monson MH. Endemic Lassa fever in Liberia. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg 1985; 79: 380-4.
35. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145: 599-609.
36. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al.; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 2 11: 80-90.
37. World Health Organization. Experimental therapies: growing interest in the use of whole blood or plasma from recovered Ebola patients (convalescent therapies). Ebola situation assessment - 26 September 2014. Available at: http://www.who.int/mediacentre/news/ebola/26-september-2014/en/. Accessed on 21/05/2015.
38. Report of an International Commission. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978; 56: 271-93.
39. Enria DA, Briggiler AM, Fernández NJ, et al. Importance of dose of neutralizing antibodies in treatment of Argentine hemorrhagic fever with immune plasma. Lancet 1984; 2: 255-6.
40. Maiztegui JI, Fernández NJ, de Damilano AJ Efficacy of immune plasma in treatment of Argentine hemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979; 2: 1216-7.
41. Enria DA, Maiztegui JI. Antiviral treatment of argentine hemorrhagic fever. Antivir Res 1994; 23: 23-31.
42. Enria DA, Briggiler AM, Sánchez Z. Treatment of Argentine hemorrhagic fever. Antivir Res 2008; 78: 132-9.
43. Ruggiero HA, Pérez Isquierdo F, Milani HA, et al. [Treatment of Argentine hemorrhagic fever with convalescent's plasma. 4433 cases]. Presse Med 1986; 15: 2239-42. [In French.]
44. Bajpai S, Nadkar MY. Crimean Congo hemorrhagic fever: requires vigilance and not panic. JAPI 2011; 59: 164-7.
45. Jahrling PB, Geisbert J, Swearengen JR, et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 1996; 11: 135-40.
46. Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferonalpha2b for treatment of experimental Ebola virus infections. J Infect Dis 1999; 179: S224-34.
47. Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis 1999; 179: S218-23.
48. Parren PW, Geisbert TW, Maruyama T, et al. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002; 76: 6408-12.
49. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179: S18-23.
50. Oswald WB, Geisbert TW, Davis KJ, et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007; 3: e9.
51. Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. PNAS 2012; 13: 5034-9.
52. Olinger GG, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA 2012; 109: 18030-5.
53. Qiu X, Audet J, Wong G, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012; 4: 138ra81.
54. European Commission. HORIZON 2020 WORK PROGRAMME 2014-2015. European Commission Decision C (2014) 4995 of 22 July 2014. Available at: http://ec.europa.eu/research/participants/portal/doc/call/h2020/common/1617601-part-1-introduction-v2.0-en.pdf. Accessed on 21/05/2015.
55. Cohen J. Ebola vaccine: little and late. Science 2014; 345: 1441-42.
56. McElroy AK, Akondy RS, Davis CW, et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci USA 2015; 11 2: 4719-24.
57. Gulland A. First Ebola treatment is approved by WHO Br Med J 2014; 349: 5539.
58. World Health Organization. Community engagement and education, recruitment and retention of people recovered from Ebola as potential donors for convalescent whole blood and plasma. Interim guidance for National Health Authorities, Blood Transfusion Services and researchers. April 2015. Available at: http://www.who.int/bloodsafety/interim-guidance-CWB-CP.pdf. Accessed on 21/05/2015.
59. World Health Organization. Ethics of using convalescent whole blood and convalescent plasma during the Ebola epidemic. Interim guidance for ethics review committees, researchers, national health authorities and blood transfusion services. 2015. Available at: http://apps.who.int/iris/bitstream/10665/161912/1/WHO-HIS-KER-GHE-15.1-eng.pdf?ua=1&ua=1. Accessed on 21/05/2015.
60. World Health Organization. Essential medicines and health products. Available at: http://www.who.int/medicines/ebola-treatment/emp-ebola-therapies/en/. Accessed on 21/05/2015.
61. Clinical Research Management, Inc. Clinical trial to evaluate the efficacy and safety of convalescent plasma for Ebola treatment (EVD001). ClinicalTrials.gov Identifier: NCT02333578. Available at: https://clinicaltrials.gov/ct2/show/NCT02333578. Accessed on 21/05/2015.
62. European Centre for Disease Prevention and Control. Overview of Ebola research - March 2015 ECDC. Treatment and vaccine development. Last updated 5 March 2015 Available at: http://ecdc.europa.eu/en/healthtopics/ebola-marburg-fevers/Pages/treatment-vaccines.aspx. Accessed on 21/05/2015.
63. Gutfraind A, Meyers LA. Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia. J Infect Dis 2015; 2 11: 1262-7.
64. European Blood Alliance. Newsletter 2015-1. Available at: http://www.sweba.se/sites/default/files/EBA%20Newsletter%202015-1.pdf. Accessed on 21/05/2015.
65. European Centre for Disease Prevention and Control. Treatment and vaccine development. Last updated 5 March 2015. Available at: http://ecdc.europa.eu/en/healthtopics/ebola-marburg-fevers/Pages/treatment-vaccines.aspx. Accessed on 21/05/2015.
66. The New York Times. How many Ebola patients have been treated outside of Africa? Updated Jan. 26, 2015 Available at: http://www.nytimes.com/interactive/2014/07/31/world/africa/ebola-virus-outbreak-qa.html?-r=0. Accessed on 21/05/2015.
67. Cerus Corporation. Press Release Details, 10/20/2014. Cerus Submits Compassionate Use IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent Plasma. Available at: http://www.cerus.com/Investors/Press-Releases/Press-Release-Details/2014/Cerus-Submits-Compassionate-Use-IDE-Supplement-for-INTERCEPT-Blood-System-Treatment-of-Ebola-Convalescent-Plasma/. Accessed on 21/05/2015.
68. Picker SM Current methods for the reduction of blood-borne pathogens: a comprehensive literature review. Blood Transfus 2013; 11: 343-8.
69. Burnouf T, Goubran HA, Radosevich M, et al. A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable bag system. Transfusion 2006; 46: 2100-8.
70. Liumbruno GM, Franchini M. Solvent/detergent plasma: pharmaceutical characteristics and clinical experience. J Thromb Thrombolysis 2015; 39: 118-28.
71. Vetter P, Schibler M, Dayer JA, Kaiser L. Ebola: the unexpected emerging disease. Rev Med Suisse 2015; 11: 877-83.
72. Colebunders RL, Cannon RO. Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease. J Infect Dis 2015; 2 11: 1208-10.
73. Katz LM, Tobian AAR Ebola virus disease, transmission risk to laboratory personnel, and pretransfusion testing. Transfusion 2014; 54: 3247-51.
74. Ubol S, Halstead SB. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol 2010; 17: 1829-35.
75. Boonnak K, Slike BM, Burgess TH, et al. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol 2008; 82: 939-51.
76. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 2013; 158: 1445-59.
77. Halstead SB Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr 2014; 2: AID-0022-2014.
78. Wang SF, Tseng SP, Yen CH, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun 2014; 451: 208-14.
79. Tirado SM, Yoon KJ. Antibody-dependent enhancement of virus infection and disease, Viral Immunol 2003; 16: 69-86.
80. Olsen CW, Corapi WV, Ngichabe CK, et al. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J Virol 1992; 66: 956-65.
81. Wong HK, Lee CK, Hung IF, et al. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection Transfusion 2010; 50: 1967-71.